Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 15,000 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.81, for a total value of $312,150.00. Following the sale, the insider owned 395,467 shares in the company, valued at approximately $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Brian Daniel Webster also recently made the following trade(s):

• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.
• On Wednesday, April 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.04, for a total value of $300,600.00.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $19.08 on Thursday. The stock’s 50-day moving average is $20.70 and its two-hundred day moving average is $22.92. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32. Kestra Medical Technologies, Ltd. has a 1-year low of $13.25 and a 1-year high of $30.00. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -4.82 and a beta of 0.83.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The company had revenue of $24.55 million for the quarter. The company’s quarterly revenue was up 62.7% on a year-over-year basis. Analysts forecast that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

Analysts Set New Price Targets

KMTS has been the topic of several recent research reports. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. BTIG Research reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. Finally, The Goldman Sachs Group lowered their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $27.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KMTS. Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter worth about $11,036,000. Woodline Partners LP purchased a new position in Kestra Medical Technologies during the 1st quarter worth approximately $2,510,000. Jane Street Group LLC purchased a new position in Kestra Medical Technologies during the 1st quarter worth approximately $756,000. Geode Capital Management LLC grew its stake in Kestra Medical Technologies by 718.5% during the 2nd quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock worth $5,395,000 after buying an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in Kestra Medical Technologies during the 2nd quarter worth approximately $256,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.